• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一名多关节型幼年特发性关节炎患者在使用托珠单抗输注后不久发生间质性肺病：病例报告

Interstitial lung disease occurring shortly after tocilizumab infusion in a patient with polyarticular juvenile idiopathic arthritis: a case report.

作者信息

Sugihara Koichi, Wakiya Risa, Shimada Hiromi, Kato Mikiya, Kameda Tomohiro, Nakashima Shusaku, Mansour Mai Mahmoud Fahmy, Ushio Yusuke, Kadowaki Norimitsu, Dobashi Hiroaki

机构信息

Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan.

出版信息

Allergy Asthma Clin Immunol. 2021 Sep 8;17(1):90. doi: 10.1186/s13223-021-00594-7.

DOI:10.1186/s13223-021-00594-7
PMID:34496961
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8424947/
Abstract

BACKGROUND

Tocilizumab has been shown to be effective for treatment of juvenile idiopathic arthritis (JIA). To our knowledge, this is the first reported case of interstitial lung disease occurring shortly after tocilizumab infusion in a patient with JIA.

CASE PRESENTATION

A 14-year-old female patient with polyarticular JIA developed interstitial lung disease after intravenous and subcutaneous administration of tocilizumab. Her condition improved with glucocorticoid therapy.

CONCLUSION

Our results suggest that increased interleukin-6 levels in the blood following tocilizumab treatment may be linked to development of interstitial lung disease.

摘要

背景

托珠单抗已被证明对治疗幼年特发性关节炎（JIA）有效。据我们所知，这是第一例报告的在JIA患者中静脉输注托珠单抗后不久发生间质性肺病的病例。

病例介绍

一名14岁多关节型JIA女性患者在静脉和皮下注射托珠单抗后发生间质性肺病。她的病情通过糖皮质激素治疗得到改善。

结论

我们的结果表明，托珠单抗治疗后血液中白细胞介素 - 6水平升高可能与间质性肺病的发生有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63e3/8424947/ff15f00385a0/13223_2021_594_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63e3/8424947/6111b3de86c0/13223_2021_594_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63e3/8424947/9cb699ad9210/13223_2021_594_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63e3/8424947/a105bb70acfb/13223_2021_594_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63e3/8424947/ff15f00385a0/13223_2021_594_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63e3/8424947/6111b3de86c0/13223_2021_594_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63e3/8424947/9cb699ad9210/13223_2021_594_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63e3/8424947/a105bb70acfb/13223_2021_594_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63e3/8424947/ff15f00385a0/13223_2021_594_Fig4_HTML.jpg

相似文献

1
Interstitial lung disease occurring shortly after tocilizumab infusion in a patient with polyarticular juvenile idiopathic arthritis: a case report.一名多关节型幼年特发性关节炎患者在使用托珠单抗输注后不久发生间质性肺病：病例报告
Allergy Asthma Clin Immunol. 2021 Sep 8;17(1):90. doi: 10.1186/s13223-021-00594-7.
2
Tocilizumab treatment in juvenile idiopathic arthritis patients: A single center experience.托珠单抗治疗幼年特发性关节炎患者：单中心经验
Turk J Pediatr. 2019;61(2):180-185. doi: 10.24953/turkjped.2019.02.005.
3
Tocilizumab for treating juvenile idiopathic arthritis.托珠单抗治疗幼年特发性关节炎。
Expert Opin Biol Ther. 2016;16(4):559-66. doi: 10.1517/14712598.2016.1150997. Epub 2016 Feb 27.
4
Patient satisfaction and clinical effectiveness of switching from intravenous tocilizumab to subcutaneous tocilizumab in patients with juvenile idiopathic arthritis: an observational study.从静脉注射托珠单抗转换为皮下注射托珠单抗治疗幼年特发性关节炎患者的患者满意度和临床疗效：一项观察性研究。
Rheumatol Int. 2020 Jul;40(7):1111-1116. doi: 10.1007/s00296-020-04596-3. Epub 2020 May 16.
5
Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial.托珠单抗治疗多关节病程幼年特发性关节炎的疗效和安全性：III 期临床试验的开放标签 2 年扩展研究。
Arthritis Rheumatol. 2021 Mar;73(3):530-541. doi: 10.1002/art.41528. Epub 2021 Feb 9.
6
Tocilizumab for the treatment of juvenile idiopathic arthritis.托珠单抗治疗幼年特发性关节炎。
Ann Pharmacother. 2012 Jun;46(6):822-9. doi: 10.1345/aph.1Q756. Epub 2012 May 15.
7
Tocilizumab: The evidence for its place in the treatment of juvenile idiopathic arthritis.托珠单抗：其在幼年特发性关节炎治疗中地位的证据
Core Evid. 2010 Jun 15;4:181-9. doi: 10.2147/ce.s5992.
8
Radiological improvement by tocilizumab in polyarticular juvenile idiopathic arthritis.托珠单抗治疗多关节型幼年特发性关节炎的放射学改善情况
Pediatr Int. 2015 Apr;57(2):307-10. doi: 10.1111/ped.12454.
9
Efficacy and safety of tocilizumab in a real-life observational cohort of patients with polyarticular juvenile idiopathic arthritis.托珠单抗治疗多关节型幼年特发性关节炎真实世界观察性队列研究的疗效和安全性。
Rheumatology (Oxford). 2020 Apr 1;59(4):732-741. doi: 10.1093/rheumatology/kez291.
10
Clinical improvement of renal amyloidosis in a patient with systemic-onset juvenile idiopathic arthritis who received tocilizumab treatment: a case report and literature review.1例全身型幼年特发性关节炎患者接受托珠单抗治疗后肾淀粉样变性的临床改善：病例报告及文献复习
BMC Nephrol. 2017 May 12;18(1):159. doi: 10.1186/s12882-017-0573-y.

引用本文的文献

1
Drug-Induced Pulmonary Fibrosis: National Database Analysis.药物性肺纤维化：全国数据库分析
Biomedicines. 2024 Nov 21;12(12):2650. doi: 10.3390/biomedicines12122650.
2
Clinical Presentation and Treatment of Juvenile Idiopathic Arthritis Combined with Lung Disease: A Narrative Review.幼年特发性关节炎合并肺部疾病的临床表现与治疗：一项叙述性综述
Rheumatol Ther. 2023 Jun;10(3):507-522. doi: 10.1007/s40744-023-00542-4. Epub 2023 Mar 11.
3
Immune-related adverse events of biological immunotherapies used in COVID-19.用于治疗新冠肺炎的生物免疫疗法的免疫相关不良事件。

本文引用的文献

1
Organizing Pneumonia Induced by Tocilizumab in a Patient with Rheumatoid Arthritis.托珠单抗诱发类风湿关节炎患者的机化性肺炎
Cureus. 2020 Feb 13;12(2):e6982. doi: 10.7759/cureus.6982.
2
Nonspecific interstitial pneumonia in refractory systemic juvenile idiopathic arthritis responded to tocilizumab treatment.难治性全身型幼年特发性关节炎中的非特异性间质性肺炎对托珠单抗治疗有反应。
Asian Pac J Allergy Immunol. 2022 Jun;40(2):172-176. doi: 10.12932/AP-050819-0616.
3
Risk factors for hypersensitivity reactions to tocilizumab introduction in systemic juvenile idiopathic arthritis.
Front Pharmacol. 2022 Aug 25;13:973246. doi: 10.3389/fphar.2022.973246. eCollection 2022.
全身型幼年特发性关节炎患者使用托珠单抗引发超敏反应的危险因素。
Mod Rheumatol. 2019 Mar;29(2):324-327. doi: 10.1080/14397595.2018.1457490. Epub 2018 Apr 16.
4
Serum interleukin 6 levels as a useful prognostic predictor of clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease.血清白细胞介素6水平作为快速进展性间质性肺病的临床无肌病性皮肌炎的有用预后预测指标。
Mod Rheumatol. 2014 Jul;24(4):633-6. doi: 10.3109/14397595.2013.844390. Epub 2013 Nov 4.
5
Exacerbation of combined pulmonary fibrosis and emphysema syndrome during tocilizumab therapy for rheumatoid arthritis.类风湿关节炎患者接受托珠单抗治疗期间合并肺纤维化和肺气肿综合征病情加重
Joint Bone Spine. 2013 Dec;80(6):670-1. doi: 10.1016/j.jbspin.2013.03.009. Epub 2013 Apr 23.
6
Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis.系统性幼年特发性关节炎中的肺动脉高压和其他潜在致命性肺部并发症。
Arthritis Care Res (Hoboken). 2013 May;65(5):745-52. doi: 10.1002/acr.21889.
7
A case of organizing pneumonia induced by tocilizumab.一例由托珠单抗诱发的机化性肺炎。
Intern Med. 2011;50(19):2191-3. doi: 10.2169/internalmedicine.50.5497. Epub 2011 Oct 1.
8
Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients.日本托珠单抗治疗类风湿关节炎的上市后监测：3881 例患者的中期分析。
Ann Rheum Dis. 2011 Dec;70(12):2148-51. doi: 10.1136/ard.2011.151092. Epub 2011 Aug 17.
9
Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions.全身性幼年特发性关节炎的发病机制：部分答案，更多疑问。
Nat Rev Rheumatol. 2011 Jun 7;7(7):416-26. doi: 10.1038/nrrheum.2011.68.
10
A case of multicentric Castleman's disease having lung lesion successfully treated with humanized anti-interleukin-6 receptor antibody, tocilizumab.一例肺病变的多中心 Castleman 病经人源化抗白细胞介素-6 受体抗体托珠单抗治疗后成功缓解。
J Korean Med Sci. 2010 Sep;25(9):1364-7. doi: 10.3346/jkms.2010.25.9.1364. Epub 2010 Aug 12.